NuVasive

The post-earnings selloff at a medical device maker has brought out some insiders. Two directors and an executive vice president have acquired almost 26,100 shares this past week. Insider buying often can be seen as a good sign for investors. Conventional wisdom says that insiders and...

NuVasive, Inc. (NASDAQ: NUVA), a global medical device company in the spine market, announced on Tuesday it has agreed to acquire Ellipse Technologies for $380 million upfront and a potential $30 million milestone payment. Ellipse Technologies is a privately held medical technology company focused...

Insiders may buy shares of a company because they believe its stock price will move higher and want to profit from this anticipated rise. Sell-offs might provide an opportunity for insiders who have faith in a company to snatch up shares. Below are some stocks that have recently seen insider buying...

J.P. Morgan has published a report on NuVasive Inc (NASDAQ: NUVA) raising the price target from $33 to $34. In the report, J.P. Morgan wrote, "Nuvasive reported solid 2Q results Monday after the close, with revenues of $133.0M (+11.2%) coming in $500k above our estimate and $1.0M better than...

iShares Dow Jones US Healthcare Provider (NYSE: IHF) is up more than 19% year to date. The fund invests at least 90% of its assets in securities of the underlying index, which measures the performance of the health care providers sector of the U.S. equity market. Top holdings include UnitedHealth...

PowerShares S&P SmallCap Health Care (NYSE: PSCH) is up nearly 22% year to date. The investment seeks to replicate the S&P SmallCap 600 Capped Health Care index, which is comprised of common stocks of U.S. health care companies. Top holdings include Regeneron Pharmaceuticals (NASDAQ: REGN...

Bank of America provided color on NuVasive (NASDAQ: NUVA). In a research report published today, Bank of America stressed its optimism about the company's long-term performance. In the report, Bank of America states, "Our bullish call on NUVA is based on the simple premise that because of its low...

Bank of America Merrill Lynch is out with its report today on Nuvasive (NASDAQ: NUVA), reiterating Buy. In a note to clients, Bank of America Merrill Lynch writes, "At just 2.4x 2011E EV/sales NUVA trades well below peer valuations primarily because investors are worried about the spine mkt....

According to Jefferies, NuVasive (NYSE: NUVA) reported a 1Q result that beat on both revenue and earnings. Jefferies said that the revenue beat was driven by better performance out of the core lumbar business; the EPS beat was mostly non-operational. “The spine market remains challenging, but the...

J.P. Morgan, which raised its PT on shares of NuVasive, Inc. (NASDAQ: NUVA), is providing color on the stock. “NuVasive reported strong 1Q results Wednesday after the close, with revenues of $124.5M (+20.9%) coming in $1.1M above our estimate and $1.4M better than consensus,” J.P. Morgan writes. “...

JP Morgan has raised the price target on NuVasive (NASDAQ: NUVA) from $29 to $33 and maintains its Neutral rating.